EUVIMEDOtkrijte EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Early Cancer Detection: What's Going on and What's Next

Emma Di Carlo iD

MedComm · 2026-03 · 7 (3)

DOI: 10.1002/mco2.70653 ↗

At a glance

Übersichtsarbeit in MedComm, published online on 2026-03-11. Written by Emma Di Carlo. Institution: Department of Medicine and Sciences of Aging "G. d'Annunzio" University of Chieti-Pescara Chieti Italy. Cited 2 times so far (Crossref); 189 references. The full text is freely available (open access, CC BY 4.0). Funded by: Ministero della Salute, Associazione Italiana per la Ricerca sul Cancro.

SažetakSubjectsBibliografski podaciCiteRelated studies

Abstract (original language)

Late‐stage cancer diagnosis and limited treatment options for advanced disease remain major contributors to cancer‐related morbidity and mortality. Blood‐based multicancer early detection (MCED) assays have consequently gained momentum as a means to shift diagnosis toward earlier, more curable stages. Despite their promise, substantial methodological, clinical, and implementation barriers hinder widespread adoption. Integrative approaches coupling multi‐omics profiling with advanced molecular imaging may improve detection accuracy and tumor localization, while risk‐adapted MCED paradigms could support more targeted, individualized screening strategies. This article reviews the current landscape of MCED technologies, with a primary focus on circulating cell‐free DNA and circulating tumor DNA–based assays, and critically evaluates their developmental status, strengths, and limitations relative to established single‐cancer screening methods. The contribution of artificial intelligence, particularly advanced deep learning, to improving sensitivity, specificity, and predictive performance is discussed. The potential of MCED assays to detect aggressive, currently unscreened malignancies and to address the unique challenges of pediatric cancers is examined. In addition, emerging alternative detection strategies, ongoing clinical validation efforts, regulatory requirements, and implementation considerations are reviewed. Finally, the impact of MCED testing on cancer mortality, quality of life, and healthcare systems is outlined, along with key technological trends shaping future development and clinical translation.

Subjects

Author keywords

artificial intelligence modelscirculating cell‐free DNAearly cancer diagnosisliquid biopsymulticancer early detection teststumor‐associated biomarkers

Authors and institutions

  • Department of Medicine and Sciences of Aging "G. d'Annunzio" University of Chieti-Pescara Chieti Italy.
  • Anatomic Pathology and Immuno-Oncology Unit Center for Advanced Studies and Technology (CAST) "G. d'Annunzio" University of Chieti-Pescara Chieti Italy.

ORCID profiles: Emma Di Carlo

Funding

  • Ministero della Salute
  • Associazione Italiana per la Ricerca sul Cancro

Cite

APA

Di Carlo, E. (2026). Early Cancer Detection: What's Going on and What's Next. MedComm, 7(3). https://doi.org/10.1002/mco2.70653

Vancouver

Di Carlo E. Early Cancer Detection: What's Going on and What's Next. MedComm. 2026;7(3). doi:10.1002/mco2.70653

BibTeX
@article{DiCarlo2026,
  author = {Di Carlo, Emma},
  title = {Early Cancer Detection: What's Going on and What's Next},
  journal = {MedComm},
  year = {2026},
  volume = {7},
  number = {3},
  doi = {10.1002/mco2.70653}
}
Start for free →